Literature DB >> 27426476

CLOVES syndrome: review of a PIK3CA-related overgrowth spectrum (PROS).

A Martinez-Lopez1, G Blasco-Morente1, I Perez-Lopez1, J D Herrera-Garcia2, M Luque-Valenzuela3, D Sanchez-Cano4, J C Lopez-Gutierrez5, R Ruiz-Villaverde1, J Tercedor-Sanchez1.   

Abstract

Overgrowth syndromes are characterized by global or localized disproportionate growth associated with other anomalies, including vascular malformations and neurological and/or visceral disorders. CLOVES (Congenital Lipomatous asymmetric Overgrowth of the trunk with lymphatic, capillary, venous, and combined-type Vascular malformations, Epidermal naevi, Scoliosis/Skeletal and spinal anomalies) is an overgrowth syndrome caused by mosaic activating mutation in gene PIK3CA, which gives rise to abnormal PI3K-AKT-mTOR pathway activation. These mutations are responsible for the clinical manifestations of the syndrome, which include low- and high-flow vascular malformations, thoracic lipomatous hyperplasia, asymmetric growth, and visceral and neurological disorders. These common anomalies are illustrated with figures from two personal cases. Identification of the clinical and genetic characteristics of CLOVES syndrome is crucial for the differential diagnosis with other overgrowth syndromes, such as Proteus or Klippel-Trenaunay (K-T) syndromes, and for the therapeutic management of the different anomalies. In this context, a new entity comprising different syndromes with phenotypic mutations in PIK3CA has been proposed, designated PIK3CA-related overgrowth spectrum (PROS), with the aim of facilitating clinical management and establishing appropriate genetic study criteria.
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  CLOVES syndrome; PIK3CA; PIK3CA-related overgrowth spectrum; overgrowth syndromes

Mesh:

Substances:

Year:  2016        PMID: 27426476     DOI: 10.1111/cge.12832

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  26 in total

Review 1.  Clinical and sonographic features of pediatric soft-tissue vascular anomalies part 2: vascular malformations.

Authors:  Craig M Johnson; Oscar M Navarro
Journal:  Pediatr Radiol       Date:  2017-08-04

2.  Signaling pathways and inhibitors of cells from patients with kaposiform lymphangiomatosis.

Authors:  Elisa Boscolo; Patricia Pastura; Kathryn Glaser; Jillian Goines; Adrienne M Hammill; Denise M Adams; Peter Dickie; Belinda Hsi Dickie; Timothy D Le Cras
Journal:  Pediatr Blood Cancer       Date:  2019-05-02       Impact factor: 3.167

Review 3.  Overgrowth syndrome in neonates: a rare case series with a review of the literature.

Authors:  Aakash Pandita; Astha Panghal; Girish Gupta; Kirti M Naranje
Journal:  BMJ Case Rep       Date:  2019-01-17

Review 4.  Vascular anomalies: clinical perspectives.

Authors:  Joao Guilherme Amaral; Irene Lara-Corrales
Journal:  Pediatr Radiol       Date:  2022-01-05

5.  PI3K and AKT at the Interface of Signaling and Metabolism.

Authors:  Giovanni Solinas; Barbara Becattini
Journal:  Curr Top Microbiol Immunol       Date:  2022       Impact factor: 4.737

Review 6.  Neurodevelopmental disorders, immunity, and cancer are connected.

Authors:  Ruth Nussinov; Chung-Jung Tsai; Hyunbum Jang
Journal:  iScience       Date:  2022-05-30

Review 7.  Insulin-PI3K signalling: an evolutionarily insulated metabolic driver of cancer.

Authors:  Benjamin D Hopkins; Marcus D Goncalves; Lewis C Cantley
Journal:  Nat Rev Endocrinol       Date:  2020-03-03       Impact factor: 43.330

Review 8.  Neonatal vascular anomalies manifesting as soft-tissue masses.

Authors:  Nadeen Abu Ata; Adrienne M Hammill; Arnold C Merrow
Journal:  Pediatr Radiol       Date:  2021-08-10

9.  The effect of rapamycin, NVP-BEZ235, aspirin, and metformin on PI3K/AKT/mTOR signaling pathway of PIK3CA-related overgrowth spectrum (PROS).

Authors:  Yasuyo Suzuki; Yasushi Enokido; Kenichiro Yamada; Mie Inaba; Kumiko Kuwata; Naoki Hanada; Tsuyoshi Morishita; Seiji Mizuno; Nobuaki Wakamatsu
Journal:  Oncotarget       Date:  2017-07-11

10.  The combined prevalence of classified rare rheumatic diseases is almost double that of ankylosing spondylitis.

Authors:  Judith Leyens; Tim Th A Bender; Martin Mücke; Christiane Stieber; Dmitrij Kravchenko; Christian Dernbach; Matthias F Seidel
Journal:  Orphanet J Rare Dis       Date:  2021-07-22       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.